SEC Comment Letter 0000000000-25-000373 to Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc.
Date: Jan. 14, 2025 · CIK: 0001750149 · Accession: 0000000000-25-000373
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284222
Letter
January 14, 2025 Milton H. Werner Chief Executive Officer Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 Re:Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284222 Dear Milton H. Werner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Marishka DeToy
Show Raw Text
January 14, 2025
Milton H. Werner
Chief Executive Officer
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway SE, Suite 1900
Atlanta, GA 30339
Re:Inhibikase Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 10, 2025
File No. 333-284222
Dear Milton H. Werner:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Marishka DeToy